Business
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation will highlight data from an expanded cohort totaling 55 first-line patients - NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that updated
About this update from Immuneering Corporation
[{"type":"image","alt":"Immuneering Corporation","displaySize":"","headline":null,"caption":"Immuneering Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/0b858d23fa378250fb0126249c47625c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/soL0WMy1eyfRS2pEhmbQlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgz/https://media.zenfs.com/en/globenewswire.com/0b858d23fa378250fb0126249c47625c","width":300,"height":59}},"lazy":false},{"type":"text","content":"- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -","length":178,"tagName":"p"},{"type":"text","content":"- The ASCO presentation will highlight data from an expanded cohort totaling 55 first-line patients -","length":101,"tagName":"p"},{"type":"text","content":"NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that updated data from the Phase 2a clinical trial evaluating atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients will be presented as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.","length":563,"tagName":"p"},{"type":"text","content":"The oral presentation will highlight data from an expanded cohort totaling 55 first-line patients, which includes the initial cohort of 34 patients that the company previously reported plus an additional 21 patients.","length":216,"tagName":"p"},{"type":"text","content":"“We are excited to present new survival data from an expanded cohort of 55 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in an oral presentation at ASCO,” said Ben Zeskind, Ph.D., CEO of Immuneering. “Atebimetinib was designed with three distinct mechanisms to promote survival: shrinking tumors durably, preserving body mass, and maximizing tolerability. We believe these mechanisms have the potential to both yield the best survival in the first-line setting, and to give patients the best chance of reaching and benefi...